PRS36 The Cost-Effectiveness of Step Down from High Dose ICS/Laba Combination Therapy in Asthma in the UK Setting  by Paggiaro, P. et al.
meant these patients had greatest propensity for quality-of-life improvements and
QALY gains, resulting in the public subsidy recommendation in this patient sub-
group by the PBAC in Australia. CONCLUSIONS: Patients using MOCS with a base-
line ACQ-5 2.0 or AQLQ 5.0 are those in whom OM shows optimal cost-effec-
tiveness in the Australian healthcare environment.
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OBJECTIVES: To assess the cost-effectiveness of indacaterol in comparison to
tiotropium and formoterol from Brazilian public healthcare system perspective.
METHODS: A Markov model was designed to project costs and outcomes associ-
ated with disease progression of patients with COPD over 3-years time horizon. The
model health states are divided by severity of COPD (mild, moderate, severe and
very severe) with each of these states divided into three states: no exacerbation,
non-severe and severe exacerbations. The target population consists of patients
with moderate or severe COPD, and the health states for mild and very severe COPD
are included to account for those who improve in first cycle to the mild state and
those who progress to very severe state over time. Efficacy data and exacerbation
rates were obtained from the pivotal trials. Mortality data for COPD-specific states
are based on study by Rutten-van Mölken et al. COPD related medical resource
utilization patterns were assessed through clinical experts’ panel. Unit costs were
extracted from Brazilian official lists. Outcomes are expressed as life years gained
(LYG). One-way sensitivity analysis was performed. Annual discount rate of 5% was
applied both to costs and outcomes. RESULTS: Base case analysis estimated incre-
mental LYG for indacaterol of 0.010 vs. formoterol and 0.006 vs. tiotropium. Inda-
caterol was cost-saving as compared to tiotropium (incremental cost of -2,667BRL).
Comparing to formoterol, the projected ICER was 25,458BRL per LYG. The variables
that most influenced the results were time horizon, mortality rates and baseline
population.CONCLUSIONS: Indacaterol is a valuable alternative for COPD patients,
being a cost-saving treatment vs. tiotropium with incremental clinical benefits and
lower costs. Versus formoterol, indacaterol has incremental benefit, at a reason-
able incremental cost.
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OBJECTIVES: The objective of this analysis was to compare results of two cost-
effectiveness analyses for omalizumab added to standard therapy in severe allergic
asthma patients using an RCT (INNOVATE) compared to a real-world, prospective
observational study (EXPERIENCE). METHODS: A Markov model was developed to
examine the cost-effectiveness of add-on omalizumab versus standard care from
the perspective of the Dutch health care system over a patient’s lifetime. Efficacy
data for clinically significant (CS) exacerbations and resource use (hospital admis-
sions, unscheduled physician visits and emergency visits) were derived from IN-
NOVATE or Dutch patients enrolled in EXPERIENCE. Data from each were projected
to lifetime with discounted future costs (4%) and outcomes (1.5%). RESULTS: For
the EXPERIENCE study, the modelled direct medical costs for patients on standard
therapy were €77,615, of which 75% was for exacerbation control versus €133,475
for standard therapy  omalizumab, of which 38% was for exacerbation control.
Patients on omalizumab had more QALYs than those on standard therapy alone,
12.05 versus 10.47. The resulting ICER was €35,257/QALY for the EXPERIENCE study.
The INNOVATE costs were lower in both treatment arms: €22,499 for standard
therapy and €58,666 for standard therapy  omalizumab. Costs were lower due to
lower rate of CS exacerbations in the RCT where patients had been under best
possible control at trial entry. QALYs were similar to the EXPERIENCE study 12.05
and 10.91, respectively; resulting in €31,802/QALY. CONCLUSIONS: Decision-mak-
ers are often presented with cost-effectiveness evidence from RCTs although they
prefer to base decisions on real-world data are preferred. This study is one the first
to include both in a re-evaluation dossier. It showed differences in patient charac-
teristics (exacerbation rates and resource use) between the RCT and observational
study. However it confirmed the value of omalizumab with similar ICERs, indicat-
ing that omalizumab is cost effective in both settings.
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OBJECTIVES: To evaluate the cost-effectiveness of varenicline compared to bupro-
pion and nicotine-replacement therapy (NRT) from a third-party payer (Social In-
surance Fund) perspective in Greece. METHODS: The Benefits of Smoking Cessa-
tion on Outcomes (BENESCO) Markov model was applied to calculate the long-term
health and economic benefits of smoking cessation, simulating the incidence and
outcomes of smoking-related morbidities to a hypothetical cohort of patients (age-
and gender-representative of the Greek population) making a single quit attempt.
Demographic, epidemiological, treatment efficacy and economic inputs for the
modelled cohort were obtained from the literature and publicly available data from
public healthcare databases. The model calculated costs and outcomes for a life-
time perspective, discounted at a 3% discount rate and reported in year 2011 fees
and prices. Extensive probabilistic sensitivity analysis was performed to test the
robustness of the results. RESULTS: The cohort consisted of 819,709 current smok-
ers making a quit attempt. The respective 1year continuous abstinence rates were
22.5%, 15.5% and 15.4% for quitters under varenicline, NRT and bupropion. For a
lifetime horizon, varenicline prevented in total 7652 and 7609 additional cases of
smoking-related disease (coronary heart disease, stroke, lung cancer, chronic ob-
structive pulmonary disease) versus NRT and bupropion, respectively. Moreover,
varenicline led to a gain of 21,219 QALYs (16,955 life years) and 21,099 QALYs (16,859
life years) for the cohort, compared to NRT and bupropion. Taking direct costs into
account, varenicline produced cost-savings against both comparators for the life-
time as well as for shorter (20year) timeframes of analysis. The probabilistic sen-
sitivity analysis corroborated the study outcomes. CONCLUSIONS: Taking into ac-
count the Social Security perspective in Greece, varenicline was a dominant
smoking cessation strategy compared to NRT and bupropion, reducing both treat-
ment costs and smoking-related morbidity.
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OBJECTIVES: To estimate the cost-effectiveness of roflumilast (Daxas®) versus the
most prescribed drug combination in Spain in the treatment of adult patients with
severe chronic obstructive pulmonary disease (COPD) with a history of frequent
exacerbations. METHODS: A Markov model was constructed to estimate the life
time cost-effectiveness of roflumilast plus a long acting muscarinic antagonist
(roflumilast  LAMA) versus the combination of LAMA with a long-acting beta
agonist plus and an inhaled corticosteroid (LAMALABA/ICS). Outcomes were ex-
pressed as the incremental cost per exacerbation avoided from the Spanish Na-
tional Health System perspective using a life-time horizon (30 years). Other health
outcomes in the model include quality-adjusted life year (QALY) gained and life
years (LY) gained. The key inputs to the model are based on roflumilast pivotal
clinical trials and published epidemiological and population data. Uncertainty in
the model’s parameters was examined by sensitivity analysis. RESULTS: The re-
sults of the economic analysis have demonstrated that over the lifetime of the
treatment of patients with severe COPD and associated chronic bronchitis with a
history of frequent exacerbations, the roflumilast LAMA strategy will cost 3468 €
less than using LAMA  LABA/ICS. Over a lifetime a patient treated with a roflu-
milast LAMA is estimated to have 1.23 exacerbations less and 0.129 more QALYs
that a patient treated with LAMA LABA/ICS. Therefore, the roflumilast treatment
arm appears to be the dominating option. The sensitivity analyses showed that the
variable that has the most impact on the ICER results is the relative risk of
exacerbations. CONCLUSIONS: Roflumilast  LAMA offers a cost-effective option
for the maintenance treatment of severe COPD associated with chronic bronchitis
in patients with a history of frequent exacerbations compared with LAMA LABA/
ICS.
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OBJECTIVES: Evaluate the cost-effectiveness of indacaterol (Onbrez Breezhaler,
150g & 300g) against tiotropium (Spiriva, 18g) or formoterol (Foradil, 12g twice
daily) respectively. METHODS: A Markov model was developed describing each
COPD disease severity stage based on pre-bronchodilator FEV1 measurements re-
ported in the indacaterol clinical trials (INVOLVE & INHANCE). The outcomes as-
sessment criteria were Quality-Adjusted Life-Years (QALYs), Life Years Gained
(LYG) and exacerbation rates. A 3-year time horizon was used for the cost-utility
analysis (CUA) and a lifetime (25 year) time horizon was used for the cost-effec-
tiveness analysis (CEA). Discount rates of 3.5% were set for both costs and out-
comes and univariate sensitivity analyses were conducted. Resource utilization
was based on Greek published data and relevant costs on official NHS prices.
RESULTS: The mean number of QALYs per patient in the three-year CUA was 2.152
in the indacaterol 150g arm and 2.144 in the tiotropium arm, resulting in 0.0078
QALYs in favor of indacaterol; the total costs per patient were €9,717 in the inda-
caterol arm and €9,853 in the tiotropium arm, resulting in €136 savings in favor of
indacaterol, gaining the dominant position (lower total costs, better outcomes).
The CEA over the lifetime is similarly dominant with 10.213 LYG for indacaterol and
10.119 LYG for tiotropium and a lower cost per patient for indacaterol. The CUA
comparing indacaterol 300g and formoterol also resulted in indacaterol dominat-
ing formoterol with an incremental QALY of 0.017 (2.149 and 2.132 respectively) and
a cost saving of €48.23 compared to formoterol over 3 years. Similarly, indacaterol
dominates the CEA over a life time. Regarding exacerbation rates, although very
similar outcomes appeared among treatments, COPD treatment was less costly
with indacaterol against all other comparators. CONCLUSIONS: For patients with
moderate to severe COPD, indacaterol represents a cost-effective treatment and is
potentially cost saving for the Greek NHS.
PRS36
THE COST-EFFECTIVENESS OF STEP DOWN FROM HIGH DOSE ICS/LABA
COMBINATION THERAPY IN ASTHMA IN THE UK SETTING
Paggiaro P1, Buseghin G2, Nicolini G2, Patel S2, Iannazzo S3, Zaniolo O3, Papi A4
1University of Pisa, Pisa, Italy, 2Chiesi Farmaceutici, Parma, Italy, 3AdRes HE&OR, Turin, Italy,
4University of Ferrara, Ferrara, Italy
A493V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
OBJECTIVES: According to international guidelines on the management of asthma
(GINA), step down to the lowest dose of treatment that maintains control should be
considered for controlled patients. The aim of this analysis was to estimate the
costs and health outcomes associated with step down of controlled patients on
high dose fluticasone/salmeterol (FP/S 1000/100g daily) dry powder to either ex-
trafine beclometasone/formoterol (BDP/F 400/24g) pMDI or medium dose FP/S
(500/100g) dry powder in the UK setting. METHODS: A patient-level simulation
Markov model was defined to perform the simulation of a cohort of patients along
three comparative arms (FP/S 1000/100, FP/S 500/100, BDP/F 400/24). Transition
probabilities and healthcare resources costs were derived from patient-level data
of a recent multinational clinical trial comparing the three treatments. Direct costs
and health state utilities were sourced from published literature and UK current
prices and tariffs. The analysis was conducted from the UK National Healthcare
System perspective, over a six–month time horizon. Probabilistic sensitivity anal-
ysis was conducted. RESULTS: The analysis showed an ICER (Incremental Cost-
Effectiveness Ratio) of 57,300 GBP/QALY (Quality Adjusted Life Year) associated
with high dose FP/S 1000/100g versus extrafine BDP/F 400/24g and an ICER of
approximately 86,300 GBP/QALY associated with medium dose FP/S 500/100g ver-
sus BDP/F 400/24g. CONCLUSIONS: International guidelines recommend that
when asthma control is achieved and stabilized, treatment can be stepped down to
the lowest possible dose maintaining control. This analysis shows that maintain-
ing controlled patients on high dose FP/S is not a cost-effective strategy. Extrafine
BDP/F 400/24g daily can be considered to be a cost-effective option in the UK to
maintain control of asthmatic patients stepped down from high dose FP/S 1000/
100g daily.
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OBJECTIVES: In order to assess cost-effectiveness of SAL/FP Fen/IB versus Fen/IB
only in chronic obstructive pulmonary disease (COPD) treatment in different Rus-
sian regions we developed PHACTOR pharmacoeconomic model. METHODS: Our
model was based on the constant disease-specific data such as number of COPD
exacerbations and health care resource utilization data obtained from PHACTOR
(multicenter observational research of severe and very severe COPD). The method-
ology of PHACTOR research was published in 13th ISPOR Annual European Con-
gress (Research Abstract #PRS31). The following region-specific input data were
taken into account: drug prices (from the List of Vital and Essential Pharmaceuti-
cals), medical tariffs (from regional government regulations), gross domestic prod-
uct (GDP) per capita and average salary (from statistics service). SAL/FP  Fen/IB
was compared with Fen/IB only. ICERs (cost per COPD exacerbation avoided) were
calculated for all 83 Russian regions. Regional willingness to pay (WTP) was as-
sumed as three regional GDP per capita. RESULTS:Average yearly drug costs varied
from 29,539 RUR (Belgorod) to 35,264 RUR (Yakutia) for SAL/FP  Fen/IB treatment
and from 7,877 RUR (Altai Republic) to 9,442 RUR (Yakutia) for Fen/IB treatment.
Estimated yearly costs of COPD exacerbation treatment significantly varied from
6,552 RUR (Evreyskaya AO) to 63,053 RUR (Chukotka) for SAL/FP Fen/IB treatment
and from 12,592 RUR (Evreyskaya AO) to 109,019 RUR (Chukotka) for Fen/IB treat-
ment. SAL/FP  Fen/IB treatment was cost-saving (dominating) in 9 regions and
cost-effective in 74 regions (ICERWTP; in this regions ICERs were from 74 RUR to
4,605 RUR per COPD exacerbation avoided). CONCLUSIONS: This analysis demon-
strated that regional data had the biggest impact on final cost-effectiveness results.
In general case SAL/FP  Fen/IB treatment was cost-effective in most Russian
regions and cost-saving in some regions.
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OBJECTIVES: Daxas (roflumilast) is a new PDE4-inhibitor which targets the under-
lying inflammation in COPD. It is indicated for treating severe and very severe
COPD associated with chronic bronchitis and a history of frequent exacerbations.
The objective was to assess the incremental cost-effectiveness of using roflumilast
in a Swedish health care setting.The clinical trials for roflumilast have shown that
it consistently reduces exacerbations by approx. 20% and that it also provides a
lung function benefit of between 46-81 mL in addition to long-acting
bronchodilators. METHODS: A Markov model with a life time time horizon, one
month cycles and a discount rate of 3% was constructed using Treeage and an Excel
interface. The model uses comparator treatments relevant to Swedish guidelines
including long acting -2 agonist (LABA), inhaled corticosteroids (ICS) and long-
acting muscarinic antagonists(LAMA). All input parameters on costs and epidemi-
ology were from Swedish sources. Clinical effectiveness was based on results from
clinical trials along with indirect comparisons to address other comparators rele-
vant to the reimbursement authorities. The analysis had a societal perspective and
included lost productivity using a human capital approach. Outcomes were mea-
sured in QALYs. Uncertainty was addressed both through probabilistic sensitivity
analysis and one-way analyses of central variables. RESULTS: Treatment with ro-
flumilast (ROFL) as an add-on to LABA resulted in an incremental gain of 0.35 QALY.
From a societal perspective the ICER for LABAROFLU versus LABA was €18,000 per
QALY. The probability that LABAROFLU was cost-effective using a €50 000 threshold
was 97%. The ICER for LABAROFLU vs LABAICS was €14,500.
ROFLULAMALABAICS vs LAMALABAICS was €19,000. CONCLUSIONS: The
ICERs calculated were all well below commonly accepted willingness to pay for a
QALY in Sweden for all different comparator scenarios. The results were stable
when central variables were varied. Roflumilast is a cost-effective treatment for
severe and very severe COPD.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD) represents a consid-
erable burden on patients and health systems. Frequent exacerbations in patients
with COPD result in high healthcare costs. Roflumilast, an oral, selective phos-
phodiesterase-4 inhibitor, has been shown to reduce exacerbation rates and im-
prove lung function in patients with severe COPD. The objective of this analysis is
to estimate the long-term cost and outcomes of roflumilast added to several bron-
chodilator regimens in management of severe COPD from a health payer perspec-
tive in Switzerland. METHODS: A Markov cohort model was constructed to simu-
late the progression of disease, mortality, and exacerbation rates in patients with
COPD. Transition probabilities between severe and very severe COPD were deter-
mined from the published literature. Background mortality was expressed through
the risk of death in the general population and standardised mortality ratios (SMR);
hospital mortality was based on the published literature. A cost-effectiveness anal-
ysis was conducted for roflumilast as add-on treatment to LAMA, LABA/ICS and
LAMALABA/ICS, with the relative ratios of exacerbations rates derived from a
recently published multiple-treatment-comparison. Direct costs were sourced
from published Swiss data; utilities and disutilities of exacerbations were based on
published data. Analysis was conducted from the payer perspective in Switzerland,
for a lifetime horizon, with costs and outcomes discounted at 2.5% pa. A range of
sensitivity analyses were conducted. RESULTS: The added quality-adjusted life
years (QALY) and exacerbations avoided were: (0.275 and 2.56); (0.289 and 2.69); and
(0.278 and 2.59) for roflumilast added to LAMA, LABA/ICS, and LAMALABA/ICS
respectively. The incremental cost-effectiveness ratios (ICER) were CHF 18,512 per
QALY in LAMAroflumilast vs. LAMA, CHF 17,083 per QALY in LABA/ICSroflumilast
vs. LABA/ICS, and CHF 19,470 per QALY in LAMALABA/ICSroflumilast vs.
LAMALABA/ICS. CONCLUSIONS: For patients with severe COPD who continue to
exacerbate in clinical practice in Switzerland roflumilast can be a cost-effective
treatment option.
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POLAND
Bolisega D1, Dziewiatka M1, Fedyna M1, Ziobro M1, Rutkowski J1, Haldas M1, Barlog D2,
Dziurda D2, Glogowski C2, Rys P1, Plisko R1
1HTA Consulting, Krakow, Poland, 2GSK, Warszawa, Poland
OBJECTIVES: To evaluate cost-utility of fluticasone compared with beclometha-
sone and budesonide in COPD treatment in Poland. METHODS: A discreet event
simulation (DES) model was used to estimate utilities and costs of treatment (med-
icines, standard hospitalization, ambulatory visit cost for patients with COPD) on
fluticasone therapy in comparison to beclometasone and budesonide. Analysis
was performed from public payer’s perspective with a time horizon of 10 years.
Measures of medical effects of the therapies were obtained from a systematic
review of RCTs. The range of possible outcomes in the model included: exacerba-
tion, death, FEV1. Based on the systematic review fluticasone is more effective than
beclomethasone and budesonide in terms of FEV1 improvement. Differences in
costs and effects are presented per individual patient, described as statistically
significant (SS) or non-significant (NS) and discounted at 5% and 3.5% respectively.
Probabilistic sensitivity analysis was performed to estimate the probability that
fluticasone is cost-effective in Polish conditions (threshold about 105,000
PLN/QALY). RESULTS: The QALY difference between fluticasone and beclometha-
sone was 0.136 QALY (SS), and the cost difference was 4544 PLN (NS). In determin-
istic analysis incremental cost per QALY for fluticasone compared with beclome-
tasone was 33,333 PLN. The probability of fluticasone being cost-effective was
88.1%. The QALY difference between fluticasone and budesonide in 10 years per-
spective was 0.071 (NS). The cost difference was 9,027 PLN (SS). In deterministic
analysis incremental cost per QALY for fluticasone compared with budesonide was
127,190 PLN and exceeded the threshold. There was 44.9% chance that the flutica-
sone therapy was cost-effective in comparison with budesonide therapy.
CONCLUSIONS: Fluticasone therapy is more effective than beclomethasone (SS)
and budesonide (NS). It offers to patients with COPD an additional, pay-off thera-
peutic option.
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